General Updates

July 21, 2026 The Manager – Listing BSE Limited, P J Towers, Dalal Street, Fort, Mumbai 400001 The Manager – Listing National Stock Exchange of India Ltd. Exchange Plaza, Bandra-Kurla Complex, Bandra (E), Mumbai 400051 Subject: Resignation of Chief Financial Officer upon transition to a different role within AstraZeneca Group Dear Sir/ Madam, Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Schedule III thereto, we hereby inform that Ms. Bhavana Agrawal, Executive Director and Chief Financial Officer (‘CFO’) has communicated her resignation from the position of CFO (Key Managerial Personnel) of the Company with effect from the close of business hours on August 31, 2026, pursuant to her appointment to a regional role within the AstraZeneca Group. A copy of the resignation letter is enclosed herewith as Annexure – A. Further, the details as required under the SEBI Master Circular SEBI/HO/49/14/14(7)2025- CFD-POD2/I/3762/2026 dated January 30, 2026 are enclosed herewith as Annexure – B. Sincerely, For AstraZeneca Pharma India Limited Tanya Sanish Company Secretary & Compliance Officer ACS No. 25784 Annexure A Annexure B Sr. Particulars Resignation of Ms. Bhavana Agrawal 1. Reason for change Resignation from the position of Chief Financial Officer 2. Date of Appointment/ Close of business hours on August 31, 2026 Cessation/Term of appointment 3. Brief Profile Not applicable 4. Shareholding, if any, in the Company NIL 5. Disclosure of Relationships between Not applicable Directors